Telix Pharmaceuticals (NASDAQ:TLX) Given Outperform Rating at William Blair

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "outperform" rating restated by investment analysts at William Blair in a report issued on Wednesday,RTT News reports.

A number of other equities analysts have also weighed in on the company. HC Wainwright began coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Thursday, June 12th.

Telix Pharmaceuticals Price Performance

NASDAQ:TLX traded up $1.23 during mid-day trading on Wednesday, hitting $16.92. 105,223 shares of the company traded hands, compared to its average volume of 29,148. The stock's fifty day moving average price is $16.78 and its 200-day moving average price is $16.95. Telix Pharmaceuticals has a one year low of $13.61 and a one year high of $30.36. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78.

Hedge Funds Weigh In On Telix Pharmaceuticals

An institutional investor recently bought a new position in Telix Pharmaceuticals stock. Private Advisor Group LLC purchased a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 10,140 shares of the company's stock, valued at approximately $170,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.